Confo Therapeutics appoints Dr. Cedric Ververken as Chief Executive Officer
Brussels, September 6, 2016 [09:00 CET] – Confo Therapeutics, an emerging drug discovery
company, announces the appointment of Cedric Ververken as CEO and board member, starting
October 1. Dr. Ververken will lead the transition of Confo Therapeutics from a technology company
to a drug development company.
Cedric Ververken joins Confo Therapeutics from Ablynx, where he advanced through positions of
increasing responsibility, most recently as Vice President Business Development heading the
company’s partnering activities around specific products and Nanobody drug discovery
collaborations with top tier pharmaceutical companies. He started his career as scientist-project
manager heading cross functional R&D teams and advancing internal and partnered R&D programs.
Dr. Ververken has a PhD in bioscience engineering from KU Leuven.
Stephane van Rooijen, MD, MBA, who is stepping down as CEO, played a crucial role setting up the
company and establishing its operations. He secured the initial funding, initiated a promising
portfolio of drug development programs and recruited an outstanding team to move the
organization to the next phase. With the appointment of the new CEO the company secures the
successful transition of Confo Therapeutics into a drug discovery and development company.
“Using its breakthrough technology to go after currently undruggable GPCRs Confo Therapeutics is
building a unique portfolio of first-in-class compounds addressing various unmet medical needs,“
says Dr. Ververken. “I very much look forward to working with the world-class team at Confo to
further expand the company’s operations and support its continued growth.”
“Being able to establish and build Confo Therapeutics has been an extraordinary experience so far.
I’m glad now to hand over to Cedric, who brings over 10 years of biotech leadership experience to
Confo,” explains former CEO Stephane van Rooijen. “His expertise in drug discovery as well as in
business development complements Confo’s ambition to further expand the drug development
About Confo Therapeutics
Confo Therapeutics was founded in 2015 as VIB-VUB spin-off with support of Capricorn Venture
Partners, MINTS, PMV, QBIC, SOFI, V-Bio Ventures and VIB. Confo Therapeutics is a drug discovery
company building a portfolio of first-in-class programs on pathway selective drugs. Driven by its
proprietary CONFO® technology, the company empowers the discovery of novel agonists for superior
therapeutic intervention in a wide range of diseases.
G-protein coupled receptors (GPCRs) are attractive drug targets in the treatment of many different
conditions, playing an essential part in many life processes and influencing diseases. GPCRs are flexible
on-off switches located in the cell membrane and pass signals from outside into the cell through
CONFO®‘s technology reveals new druggable pockets stabilizing the medically relevant active signaling
state of the receptor, using Confobodies (camelid single domain antibodies). The Confobody stabilized
signaling state of the GPCR makes the target accessible for drug screening and discovery. CONFO®
technology is adding value in the drug discovery value chain beyond high throughput screening,
including structure-based screening.
Confo Therapeutics is committed to the development of new medicines to treat diseases with high
Stephane van Rooijen, CEO Confo Therapeutics
More info at: www.confotherapeutics.com